BioSpace News Archive

Change Healthcare today introduced Dx Gap Advisor™, an innovative new solution on the company’s Intelligent Healthcare Network that helps health plans and their providers ensure complete, accurate, and compliant risk adjustment data capture

Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA is highly efficacious in preventing pregnancy over five years of use.

It just got easier for case managers to help develop the next generation of colleagues working in hospitals, health plans, physician offices and across the health care landscape

INSIGHTEC®, a global medical technology innovator of incisionless surgery, today announced expansion of its executive management team.

This year has been the worst on record for violence in schools with the highest incidents of K-12 school shootings since 1970, when records on school shootings begin, according to research published by the Center for Homeland Defense and Security in partnership with and sponsored by FEMA.

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today that Omegaven® (fish oil triglycerides) injectable emulsion is now commercially available in the United States.

GeneCentric Therapeutics, Inc. today announced that it has entered into a research collaboration with the University of North Carolina at Chapel Hill (UNC) to assess patient response to immunotherapeutic drugs such as PD-1 and PDL-1 inhibitors based on bladder cancer subtypes.

UnitedHealthcare announced that it will significantly expand its Navigate4Me program to bring the benefits of personalized, holistic care to more people enrolled in its Medicare Advantage plans.

Global technology services and solutions provider, Dimension Data, and Shriners Hospitals for Children will bring virtual visits with Santa Claus to young patients and their families across four Shriners Hospital locations on Dec. 11 and 12.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to M7824, the first regulatory designation for the bifunctional immunotherapy, for the treatment of biliary tract cancer (BTC).